Analysis of the Global Human Albumin Market and Product Pipeline

Emerging Economies and Use of Human Albumin as an Excipient Present New Growth Opportunities

USD 4,950.00

* Required Fields

USD 4,950.00


Be the first to review this product

The study covers provides an assessment of the marketed and pipeline products for the global human albumin market. Segmentation by application has been provided along with additional information such as clinical trial timelines and results, and historical and projected launch timelines. The marketed and pipeline products have been broadly segmented into those used in replacement therapy (fluid-volume replacement therapy), in drug formulation and delivery, as stabilisers for vaccines, and as excipients in imaging and in-vitro fertilisation products. The market shares of the key companies operating in this space have also been listed.

Table of Contents

Executive SummaryExecutive Summary—Key FindingsExecutive Summary—Key Findings (continued)Key TrendsKey Companies to WatchMethodology and ScopeMethodology and ScopeMarket BackgroundMarket Overview—IntroductionMarket Overview—Blood Plasma ProductionBlood Plasma Market ShareDemand Analysis of Blood Plasma ProteinsHuman Albumin ProductionMarket Forecast—Human AlbuminMarket Forecast—Human Albumin DiscussionSupply Chain and Distribution NetworkSupply Chain and Distribution Network (continued)Porter’s 5 Forces AnalysisPorter’s 5 Forces Analysis (continued)Porter’s 5 Forces Analysis (continued)Human Albumin Market Share AnalysisMarket SegmentationCompetitive Landscape—Human Albumin: Marketed and Pipeline ProductsRecommendations for Data Center OperatorsCompetitive Landscape—Marketed and Pipeline ProductsMarketed Products—Replacement TherapyMarketed Products—Replacement Therapy (continued)Pipeline Products—Replacement TherapyMarketed Products—Drug Formulation and Delivery Marketed Products—Drug Formulation and Delivery (continued) Pipeline Products—Drug Formulation and Delivery Marketed Products—VaccinePipeline Products—VaccineMarketed Products—OthersPivotal Trials—Phase 3 and Phase 2Total Human Albumin Market—Major Ongoing/Recently Completed Clinical TrialsSummary of Key Products to WatchTimeline of Key Events—Launch of ProductsProduct Dashboard—Key Marketed and Phase 3 ProductsProduct Dashboard: Albuminar—CSL BehringProduct Dashboard: Albutein—GrifolsProduct Dashboard: Abraxane—CelgeneProduct Dashboard: Victoza—Novo NordiskProduct Dashboard: Recombumin—NovozymesProduct Dashboard: rIX-FP—CSL BehringConclusionConclusionsLegal DisclaimerThe Frost & Sullivan StoryThe Frost & Sullivan StoryValue Proposition: Future of Your Company & CareerGlobal PerspectiveIndustry Convergence360º Research PerspectiveImplementation ExcellenceOur Blue Ocean Strategy

Related Research

Release Date : 29-Sep-2015

Region : Global

Release Date : 29-Sep-2015

Region : Global

Release Date : 09-Sep-2015

Region : North America

Release Date : 09-Apr-2015

Region : South Asia, Middle East & North Africa

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.